fluorescent-lateral-flow-immunoassay-based-on-quantum-dots-nanobeads

Fluorescent Lateral Flow Immunoassay Based on Quantum Dots Nanobeads

Quantum dots, also known as semiconductor nanocrystals, are novel fluorescent labels for biological imaging and sensing. However, quantum dot-antibody ...

development-validation-rapid-lc-msms-method-for-carfilzomib

Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients

Carfilzomib, a second-generation proteasome inhibitor, requires therapeutic drug monitoring (TDM). This study aimed to develop and validate a sensitive ...

Naval Medical University

Second Affiliated Hospital of Naval Medical University

Development of simple, robust, and reliable detection strategy of disease biomarkers holds tremendous promise for early clinical diagnosis and prognosis of diseases. In this work, through combining a silver nanoparticle (AgNP) linked immunoassay and aggregation induced emission (AIE)-based fluorogenic Ag probe, we developed a silver-amplified fluorescence immunoassay for the detection of disease biomarkers. This method overcame the intrinsic limitations of enzymes as the dissolution of AgNPs generated numerous Ag, which could switch on the fluorogenic Ag probe driven by tetrazolate-Ag complexation. As a proof of concept, our method could be used for determining α-fetoprotein (AFP) with a linear relationship in concentrations ranging from 0.1 ng mL to 5 μg mL and a low limit of detection of 42 pg mL. Our method was successfully confirmed for the detection of AFP in real serum samples from hepatocellular carcinoma (HCC) patients, demonstrating the great potential for clinical diagnosis.

Silver-amplified fluorescence immunoassay via aggregation-induced emission for detection of disease biomarker.

Highly efficient capture and detection of circulating tumor cells (CTCs) remain elusive mainly because of their extremely low concentration in patients' peripheral blood.

Immunoengineered magnetic-quantum dot nanobead system for the isolation and detection of circulating tumor cells.

Fluorescent lateral flow immunoassay (LFA) systems are versatile tools for sensitive and quantitative detection of disease markers at the point of care. However, traditional fluorescent nanoparticle-based lateral flow immunoassays are not visible under room light, necessitate an additional fluorescent reader, and lack flexibility for different application scenarios. Herein, we report a dual-readout LFA system for the rapid and sensitive detection of C-reactive protein (CRP) in clinical samples. The system relied on the aggregation-induced emission nanobeads (AIENBs) encapsulated with red AIE luminogen, which possesses both highly fluorescent and colorimetric properties. The AIENB-based LFA in the naked-eye mode was able to qualitatively detect CRP levels as low as 8.0 mg/L, while in the fluorescent mode, it was able to quantitatively measure high-sensitivity CRP (hs-CRP) with a limit of detection of 0.16 mg/L. The AIENB-based LFA system also showed a good correlation with the clinically used immunoturbidimetric method for CRP and hs-CRP detection in human plasma. This dual-modal AIENB-based LFA system offers the convenience of colorimetric testing and highly sensitive and quantitative detection of disease biomarkers and medical diagnostics in various scenarios.

One-Component Dual-Readout Aggregation-Induced Emission Nanobeads for Qualitative and Quantitative Detection of C-Reactive Protein at the Point of Care.

Therapeutic drug monitoring of program death-1 (PD-1) inhibitor Serplulimab in cancer patients is of clinical importance in predicting treatment efficacy and assessing adverse reactions. However, the traditional liquid chromatography tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) for antibody drug monitoring are time-consuming and laborious. Herein, a quantum dot nanobeads-based lateral flow immunoassay (LFIA) is developed for rapid and accurate monitoring of the PD-1 antibody drug in 15 min. Both competitive and indirect immunoassays were investigated for PD-1 antibody drug monitoring, and the competitive assay demonstrated better sensitivity and precision. The optimized competitive LFIA had a detection of limit of 5.1 μg/mL; a linear range of 10-100 μg/mL; recovery rates of 99.2%-113.9% at the spiked concentration of 25, 50 and 100 μg/mL; and coefficients of variations (CVs,  = 10) less than 14.5% at 50 μg/mL. The assay has a negligible nonspecific reaction with the interferents of other monoclonal antibody drugs, autoantibodies, hyper lipids, hemolysis, jaundice, and whole blood samples. Method comparison with ELISA in 30 human plasma samples has a good correlation factor of  = 0.87. All in all, the developed quantum dot nanobead-based LFIA system for PD-1 antibody drug monitoring is a versatile tool for rapidly personalized drug therapy at the point of care.

ArticleTotal : 2	Year
Publication title Cited by 5	2024
Publication title	2026

Article	Year
Silver-amplified fluorescence immunoassay via aggregation-induced emission for detection of disease biomarker. Talanta\| PubMed ID: 33592717	2021
Immunoengineered magnetic-quantum dot nanobead system for the isolation and detection of circulating tumor cells. Journal of nanobiotechnology\| PubMed ID: 33892737	2021
One-Component Dual-Readout Aggregation-Induced Emission Nanobeads for Qualitative and Quantitative Detection of C-Reactive Protein at the Point of Care. Analytical chemistry\| PubMed ID: 38134291	2024
On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay. Analytical chemistry\| PubMed ID: 40583312	2025

Huanxing Han

Biography

JoVE Journal Publications

Other Publications